Slide 1: Pioneering Drug Discovery - Q1 2025 results
Pioneering Drug Discovery Q1 2025 results Scientific Operational Excellence Excellence Evotec SE, Q1 2025 results call, 06 May 2025
Slide 2: Disclaimer
Disclaimer This presentation (including any information which has been or may be supplied in writing or orally in connection herewith or in connection with any further inquiries) is being delivered on behalf of Evotec SE (the “Company”, “we,” “our” or “us”). This presentation is made pursuant to Sec
Slide 3: Agenda
Agenda 1. Business overview 2. Financials 3. Questions & Answers PAGE 3
Slide 4: Agenda: Business overview
Agenda 1. Business overview 2. Financials 3. Questions & Answers PAGE 4
Slide 5: Q1 2025 at a glance
Q1 2025 at a glance Summary Shared R&D Just – Evotec Biologics • Expansion of pipeline of high value molecular glue • Strong growth with new and existing partners degraders in strategic partnership with BMS • Continued strong demand for paradigm shift in • Evotec receives grant from Korean Governmen
Slide 6: Building blocks for value creation
Building blocks for value creation Technology and Science Leadership Drug Discovery and Just – Evotec Biologics Pre-clinical Development New ways of working Enhanced commercial model Commitment to operational excellence Focus on talent development PAGE 6
Slide 7: Leadership in next-gen Drug Discovery tools
Leadership in next-gen Drug Discovery tools Source for strategic deals Hit Lead Preclinical Decoding disease Target ID / validation … identification optimisation development Chemistry Biology CRO “Essentials” DMPK Screening Preclinical ... Next-gen Drug Discovery tools E.MPD Molecular Patient Databa
Slide 8: Next-gen platforms already operating at industrial scale
Next-gen platforms already operating at industrial scale Unprecedented volumes of data >20 k >25 >3 m Patients with deep Omics profiles iPS cell types (HTS) Transcriptome profiles (ScreenSeq ) >500 bn >250 >500 k MPD datapoints iPSC genetic disease models Proteome profiles (ScreenPep ) Novel insight
Slide 9: BMS strategic partnership based on Evotec platforms - Neurology
BMS strategic partnership based on Evotec platforms – Neuro… Building a co-owned pipeline in neuronal diseases Dec 2016 May 2018 Jan 2019 Jan 2020 Jan 2021 Oct 2021 Jan 2022 Dec 2022 Jul 2023 Jun 2024 Mar 2025 Signing of Expansion LO Expansion Expansion Expansion Targeted Expansion Programme Preclin
Slide 10: Long-term partnership with BMS in oncology
...and Oncology, relating to $ 75 m payment announced Long-term partnership with BMS in oncology Mar 2021 October 2024 May 2022 Extension Expansion into Extension of other disease area (undisclosed payment) partnership Upfront $ 200 m $ 50 m 2018 2019 2020 2021 2022 2023 2024 2025 May 2018 Q4 2020 J
Slide 11: Agenda: Financials
Agenda 1. Business overview 2. Financials 3. Questions & Answers PAGE 11
Slide 12: Strong start of JEB into 2025 - Group result at €3m adj. EBITDA
Strong start of JEB into 2025 – Group result at € 3 m adj. EBITDA Condensed income statement Q1 2025 in € m1 Q1 2025 Q1 2024 Change Comments External Revenues 200.0 208.7 (4)% In-line with group expectations Shared R&D 140.6 155.2 (9)% Shared R&D softer than expected Just – Evotec Biologics (JEB)2 5
Slide 13: Improved Operating and Investing cash flow vs. Q1 2024
Improved Operating and Investing cash flow vs. Q1 2024 Quarterly Cash Flows Q1 ‘24 Q2 ‘24 Q3 ‘24 Q4 ‘24 Q1 ‘25 • Improved Operating Cash flow (OCF) Q1 ‘25 vs. prior year period Quarterly 91.1 driven by favourable change in Cash flows, working capital in € m 16.7 74,2 • Reduced cash outflow from inve
Slide 14: Liquidity developing as expected, with headroom after loan draw down
Liquidity developing as expected, with headroom after loan draw down Quarterly liquidity development Net debt, in € m 117 173 164 43 107 • Draw down of existing R&D financing facility (€ 44 m) Liquidity at 510 compensated part of cash outflow quarter end, from operating and investing in € m activiti
Slide 15: 2025 incremental cost out initiatives on track
2025 incremental cost out initiatives on track Implementation progress of actively managed cost reduction Evotec FTE development measures in Shared R&D Measure Progress1 Just - Evotec Biologics • Remaining Priority Reset initiatives implemented • Cologne site closed end of February 2025 Shared R&D •
Slide 16: Guidance confirmed
Guidance confirmed Guidance 20251 FY 2024 Guidance 2025 Comment 5%-10% growth driven by strong JEB segment; Shared R&D in soft market Group revenues € 797 m € 840 - 880 m environment pivoting towards high- value offering Further prioritisation of scalable R&D expenditure2 € 50 m € 40 - 50 m tech-pla
Slide 17: Mid-term Outlook
Mid-term Outlook 2028 aspiration Revenue Adj. EBITDA CAGR1 margin 2024-2028 2028 8-12% >20% (FY 2024: € 797 m) (FY 2024: ~3%) Drivers Market recovery, Operating leverage, Differentiation, Mix/Value add-ons, Value add-ons Productivity, Cost optimisation PAGE 17 1 CAGR = Compound annual growth rate
Slide 18: The team is ready to take your questions
The team is ready to take your questions Christian Wojczewski Paul Hitchin Aurélie Dalbiez Cord Dohrmann CEO CFO CPO CSO PAGE 18
Slide 19: pRescaRcHnevensTors
pRescaRcHnevensTors
Slide 20: Volker Braun, Investor Relations contact
Volker Braun EVP Head of Global Investor Relations & ESG +49 (0) 40 228 999 338 (d) +49 (0) 151 1940 5058 (m) volker.braun@evotec.com